Scientific Publications and
Presentations

Safety and Efficacy of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia

Synergistic Effect of Obicetrapib and Ezetimibe on Circulating LDL Particles

Obicetrapib as an Adjunct to Stable Statin Therapy Significantly Lowers LDL-C, Non-HDL-C and Apolipoprotein B in Japanese Patients: Results from the Japan Phase 2 Study

The Evolving Role of Cholesteryl Ester Transfer Protein Inhibition Beyond Cardiovascular Disease

The combination of obicetrapib and ezetimibe lowers LDL-C in patients on high-intensity statins: results from the ROSE2 Trial (NCT05266586)

Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial (ROSE2)

Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: A randomized phase 2 trial (ROSE)

Cholesteryl ester transfer protein inhibitors: From high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?

ROSE: A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Dose Finding Study to Evaluate the Effect of Obicetrapib 5 and 10 mg as an Adjunct to High-Intensity Statin Therapy

Combination lipid-lowering therapy as first-line strategy in very high-risk patients

Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects